Reports link bone-building drugs to rare leg fracture

07/15/2008 | NYTimes.com

Case studies on a rare type of leg fracture after little or no trauma among people who took bisphosphonates for five years or more have raised concerns that long-term use of the bone-building drugs may actually weaken bones. Merck & Co.'s Fosamax was cited in the reports, and the company said it will investigate whether the fracture pattern can be found commonly in people who take bone medicines.

View Full Article in:

NYTimes.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Associate Director, Regulatory Affairs - Promotional Review
Novo Nordisk
Princeton, NJ
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA